ijms-logo

Journal Browser

Journal Browser

Systemic Sclerosis: Molecular Research and Novel Therapy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (20 August 2024) | Viewed by 454

Special Issue Editor


E-Mail Website
Guest Editor
Institut Cochin, Université Paris Cité, Paris, France
Interests: systemic sclerosis; rare disease; T cells; interstitial lung disease; autoimmunity

Special Issue Information

Dear Colleagues,

Systemic sclerosis (SSc) is a rare chronic autoimmune connective tissue disease characterized by diffuse fibrosis of the skin and internal organs and vascular abnormalities, with a prevalence of 1.47 million people worldwide (https://doi.org/10.1016/j.clim.2023.109267). The mortality rate for this disease is higher than that of other rheumatic diseases, with no cure or drug that can stop progression. Like other autoimmune diseases, systemic sclerosis occurs more frequently in women, with a peak of onset during the fifth decade of life. SSc is a rare disease and there is great heterogeneity between patients in terms of the onset, progression and characteristics. This makes diagnosis and targeted treatment even more difficult. Pathogenesis is dominated by vascular changes, autoimmunity with distinct autoantibodies and the activation of both innate and adaptive immunity. The cause of systemic sclerosis is still unknown. However, it is believed that during the early stages of the disease, an over-reactive immune system causes systemic inflammation and injury to the endothelial cells of blood vessels. The unstoppable progression of vascular and fibrotic organ damage accounts for the chronic morbidity and ensuing high mortality.

The management of SSc has improved and there is an increasing number of randomized clinical trials, with new triggers, molecular pathways and drugs emerging. Data from these trials suggest a significant potential for several new therapeutic options for SSc in the near future. Combining drugs with immunomodulatory, vascular remodeling and antifibrotic properties to address the three main features that lead to sustained disease exacerbation may be an option.

This Special Issue is dedicated to molecular research and novel therapy necessary for attaining better knowledge about the diagnosis, prognosis and treatment of SSc.

Dr. Carole Nicco
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • systemic sclerosis
  • rare disease
  • T cells
  • interstitial lung disease
  • autoimmunity
  • fibrosis
  • connectivitis
  • diffuse cutaneous systemic sclerosis
  • interstitial lung disease
  • pulmonary function test
  • scleroderma
  • digital ulcers
  • myocardial fibrosis
  • interstitial fibrosis
  • rheumatoid lung disease
  • systemic disease
  • primary biliary cholangitis
  • Raynaud syndrome
  • biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop